Global Hyponatremia Treatment Market, By Type (Pseudo Hyponatremia, True Hyponatremia, Translocational Hyponatremia, Others), Treatment (Intravenuos Fluid Therapy, Medication, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Clinics, Hospitals, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
Market Analysis and Insights: Global Hyponatremia Treatment Market
Hyponatremia treatment market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market is growing at a CAGR of 4.80% in the above-mentioned research forecast period. Increasing prevalence of hyponatremia, rising cases of pulmonary tuberculosis and rising geriatric population, among others are helping the market to grow.
High demand of new treatment options and rising preference of biological therapies also boost up the market growth. Moreover, increasing partnership and collaboration among market players, favourable government support and presence of reimbursement act as opportunity for the market growth. But, side effects associated with drugs and therapies and strict regulations may hamper the global Hyponatremia treatment market.
Hyponatremia is a kidney disorder which is an important and common clinical problem. It occurs due to inability of kidneys to excrete out a lot of water load and to allow excess intake of water. Hyponatremia is classified into three types which includes pseudo hyponatremia, true hyponatremia and translocation hyponatremia based upon on the osmolality. Pseudo hyponatremia caused due to higher amount of plasma proteins, whereas translocation hyponatremia occurs due to higher amount of osmotically active solutes including mannitol or glucose in the serum. True hyponatremia involves serum osmolality reduction and is further categorized into three types including euvolemic, hypervolemic and hypovolemic. The patients diagnosed with hyponatremia reported to have concentration of serum sodium less than 135mEq/L. The associated symptoms include neurologic symptoms including seizures, impaired mental health status or coma and death. However a mild symptom involves nausea, loss of appetite, vomiting among others. Hyponatremia can be treated by administration of intravenous fluid therapy and medications. Intravenous fluid therapy includes administration of hypertonic sodium chloride at a concentration of 3%. Medications suggested for Hyponatremia treatment involves tolvaptin, sodium acetate, hydrocortisone, others.
The number of patient population is increasing worldwide with overall 7.2 cases reported per 100,000 persons per year in the U.S. Moreover increasing cases of pulmonary tuberculosis is also driving the market growth as patients suffering from pulmonary tuberculosis reported with hyponatremia. This increasing patient’s population demands effective therapies and medication hence expected to provide market with the lucrative growth.
This hyponatremia treatment market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Global Hyponatremia Treatment Market Scope and Market Size
Hyponatremia treatment market is segmented on the basis of type, treatment, route of administration, end-users and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of type, the Hyponatremia treatment market is segmented into pseudo hyponatremia, true hyponatremia, translocational hyponatremia, others.
- On the basis of treatment, the Hyponatremia treatment market is segmented into intravenuos fluid therapy, medication, others. Medication segment is further sub-segmented into tolvaptin, sodium acetate, hydrocortisone, others.
- On the basis of route of administration, the Hyponatremia treatment market is segmented into oral, parenteral, others.
- On the basis of end-users, the Hyponatremia treatment market is segmented into clinics, hospitals, homecare, others.
- On the basis of distribution channel, the Hyponatremia treatment market has also been segmented into hospital pharmacy, retail pharmacy, online pharmacy, others.
Hyponatremia Treatment Market Country Level Analysis
Hyponatremia treatment market is analysed and market size information is provided by country, type, treatment, route of administration, end-users and distribution channel as referenced above.
The countries covered in the Hyponatremia treatment market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.
On geographical estimation, North America accounts the largest market share due to increasing prevalence of hyponatremia with overall incidence rate of 7.2 cases per 100,000 people per year and increase in number of healthcare facilities providing quality healthcare services. Europe accounts the second largest market share due to ongoing research and development activities and presence of wide product distribution network. Asia-Pacific is expected to account for the largest market share over coming years for the Hyponatremia treatment market due to increasing cases of pulmonary tuberculosis which is one of the leading causes of hyponatremia and increasing investment for development of drug manufacturing facilities.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
Hyponatremia treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Hyponatremia Treatment Market Share Analysis
Hyponatremia treatment market competitive landscape provides details by competitor, details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to Hyponatremia treatment market.
The major players covered in the Hyponatremia treatment market are Astellas Pharma US, Inc., Otsuka America Pharmaceutical, Inc., Alkem Labs, Sun Pharmaceutical Industries Ltd., MSN Laboratories, Steadfast Medishield, Centaur Pharmaceuticals, Biokindle Lifesciences Pvt. Ltd., Pfizer, Symbiotec Pharma Lab Pvt. Ltd., enveelab, Cumberland Pharmaceuticals Inc., BLDpharm among other domestic and global players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
SKU-